|
Tien Hsien Liquid is an Immunotherapy treatment which has the immune system fight off the infection or disease. It is used as a dietary supplement to help strengthen the body's immune system. In turn, the immune system then identifies, attacks and destroys tumorous or cancerous cells.  |
|
Tien Hsien Research Study Published in
American Journal of Chinese
Medicine
| Title: |
Immunomodulating Effects of "Tien-Hsien Liquid" on Peripheral
Blood Mononuclear Cells and T-Lymphocytes from Patients with
Recurrent Aphthous Ulcerations |
 |
| Source: |
The American Journal of
Chinese Medicine, Vol. 32, No. 2 (2004) 221-234 |
 |
| Copyright: |
World Scientific Publishing
Company & Institute for Advanced Research in Asian Science and
Medicine |
| Author(s): |
Andy Sun
Institute of Microbiology, College of Medicine, National
Taiwan University, ROCJean-San Chia
Institute of Microbiology, College of Medicine, National
Taiwan University, ROC
Won-Bo Wang
Institute of Microbiology, College of Medicine, National
Taiwan University, ROC |
| Abstract: |
Recurrent aphthous ulcerations (RAU) represent a common oral
mucosal disease with altered humoral and cellular immunities.
In our institution, an immunomodulating agent, levamisole, is
used to treat RAU with satisfactory therapeutic effect.
Tien-Hsien liquid (THL) is an extract of Chinese medicinal
herbs with immunomodulating effects. To test whether THL has
immunomodulating effects on antigen-stimulated proliferation
response (PR) of peripheral blood mononuclear cells (PBMC) and
T-cells isolated from RAU patients and to test whether THL is
a potential drug for treating RAU, PBMC or T-cells isolated
from RAU patients were incubated with lipopolysaccharides
(LPS) from Escherica coli, phytohemagglutinin (PHA),
staphylococcal enterotoxin B (SEB), glutaraldehyde-inactivated
tetanus toxoid (TT), glucosyltransferase D (GtfD), or antigens
of Streptococcus mutans in the presence or absence of THL. We
found that THL significantly increased the LPS-stimulated PR
of PBMC from active RAU patients, the GtfD-stimulated PR of
PBMC and of T-cells from inactive RAU patients, and the S.
mutans-stimulated PR of PBMC from inactive RAU patients.
However, THL could also significantly reduce the SEB-stimulated
PR of PBMC and of T-cells from active RAU patients and S.
mutans-stimulated PR of T-cells from active RAU patients.
These results suggest that THL can modulate the
antigen-stimulated PR of PBMC and T-cells from RAU patients.
Therefore, it may be a potential immunoceutical agent for
treatment of RAU.
|
Tien Hsien Research Study Published in
Evidence-Based Complementary and Alternative Medicine
| Title: |
Safety and Efficacy of Tien-Hsien Liquid Practical in
Patients with Refractory Metastatic Breast Cancer: A
Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group, Phase IIa Trial |
| Source: |
Evidence-Based Complementary
and Alternative Medicine
Volume 2012 (2012), Article ID 803239, 8 pages
doi:10.1155/2012/803239 |
| Copyright: |
Copyright © 2012 Wen-Hung
Kuo et al. This is an open access article distributed under
the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited. |
| Author(s): |
Wen-Hung Kuo
Department of General Surgery, National Taiwan University
Hospital, Taipi, TaiwanChien-An Yao
Department of Family Medicine, National Taiwan University
Hospital, Taipi, Taiwan
Chih Hui Lin
Gerent Biotech Co., Ltd., Taichung, Taiwan
King-Jen Chang
Department of General Surgery, National Taiwan University
Hospital, Taipi, Taiwan
Department of Surgery, Cheng Ching General Hospital,
Taichung, Taiwan |
| Abstract: |
To evaluate the safety and
efficacy of Tien-Hsien Liquid Practical (THL-P), a Chinese
herbal mixture, in patients with refractory metastatic
breast cancer, we performed a randomized, double-blind,
placebo-controlled, parallel-group, phase IIa pilot trial.
Patients were randomly assigned to either receive THL-P or
matching placebo and followed up every 4 weeks for 24 weeks.
The primary endpoint was changes in the global health
status/quality of life (GHS/QOL) scale. The secondary
endpoints were changes in functional and symptom scales,
immunomodulating effects, and adverse events. Sixty-three
patients were enrolled between June 2009 and June 2011. The
intent-to-treat population included 28 patients in the THL-P
group and 11 patients in the placebo group. Compared to the
placebo group, the THL-P group had significant improvement
from baseline to last visit in GHS/QOL (41.7 versus −33.3;
 ,
 ), CD3, CD4/CD8, CD19,
CD16+56 positive cells ( ,
 ), and higher levels of
physical, role, emotional, and cognitive functioning, as
well as decreased fatigue and systemic side effects.
Treatment-related adverse events were mild constipation and
localized itching, and no serious adverse events were
reported. THL-P appears to be a safe alternative adjuvant
treatment for patients with refractory metastatic breast
cancer, as it effectively improves QOL and palliates
cancer-related symptoms.
|
|
 |
 |
 |
 |
 |
|
Dr. Wang Zhen Guo (left) is in the First Annual Ten Best Youths of
China awards. (1990) |
Medaille De Chevalier* |
Diplome D'Officier* |
Diplome De Chevalier* |
Diplome Du Merite De
L'invention* |
|
*Awarded
in the 38th World Fair for Invention, Research and Industrial
Innovation held in Brussels. |
|
1989 - Best Individual Invention at the 38th
Brussels Eureka World Fair for Invention. (1) Medal for
Honor by the King of Belgium. (2) General Medal by the King of
Belgium. (3) Knights Medal by the King of Belgium. |
|
1990 - Recipient of the Second Annual
Technology Entrepreneurs Award in China |
|
1990 - Recipient of the National
Distinguished Contribution Award for Outstanding Young
Professional |
|
1991 - Recipient of the National Outstanding
Achievement Award for Self-Proficiency |
|
1992- Community Excellence Award for
Technology Entrepreneur in China |
|
1992 - Recognized by China as an Outstanding
Intelligent National |
|
1992 - Became the First Chinese
Traditional Doctor Recorded in the Who's Who of Intellectuals by the International
Biographical Center at Cambridge, England. |
|
1995 - National Crucial New Product of the
Year Award - Tien Hsien Liquid No. 1 |
|
1997 - Only Chinese Pharmacologist invited
to lecture at the Third Annual Japan Cancer Expo conducted by
the American Cancer Control Association. |
|
1998 - Published the latest in Anti-Cancer
Research and Developments in the Fourth Annual Japan Cancer Expo
conducted by the American Cancer Control Association |
|
|
 |
|
